Literature DB >> 1981011

Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog.

S W Lamberts1, W H Bakker, J C Reubi, E P Krenning.   

Abstract

This paper presents the results of the visualization of somatostatin (SS) receptor positive tumors in man after the i.v. administration of the SS analog Tyr3-octreotide coupled to 123I. It is an easy, quick and harmless procedure which allows imaging of primary and (often unexpected) secondary deposits and/or multiple localizations of the majority of endocrine pancreatic tumors, metastatic carcinoids and pituitary tumors, as well as of a multitude of tumors with neuroendocrine characteristics and well-differentiated brain tumors and meningiomas. In the case of hormone-secreting tumors a positive scan in most instances also predicts the subsequent successful therapy with octreotide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981011     DOI: 10.1016/0960-0760(90)90469-2

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

1.  [Clinical value of somatostatin receptor scintigraphy. Studies of pre- and intraoperative localization of gastrointestinal and pancreatic tumors].

Authors:  S Adams; R P Baum; M Adams; H J Wenisch; P M Schumm-Draeger; A Encke; K H Usadel; G Hör
Journal:  Med Klin (Munich)       Date:  1997-03-15

2.  [Somatostatin in preoperative therapy and postoperative diagnosis of a patient with Verner Morrison syndrome].

Authors:  R J Weinel; C Neuhaus; J Stapp; H J Klotter; M E Trautmann; R Arnold; K Josef; M Rothmund
Journal:  Langenbecks Arch Chir       Date:  1992

Review 3.  Exendin-4 analogs in insulinoma theranostics.

Authors:  Tom J P Jansen; Sanne A M van Lith; Marti Boss; Maarten Brom; Lieke Joosten; Martin Béhé; Mijke Buitinga; Martin Gotthardt
Journal:  J Labelled Comp Radiopharm       Date:  2019-08       Impact factor: 1.921

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.